Connect Biopharma's Rademikibart Shows Strong Phase 2 Results in COPD Exacerbations
Event summary
- Rademikibart reduced treatment failure rate by 81% compared to placebo in COPD patients with type 2 inflammation.
- The drug eliminated hospitalizations and emergency department visits for new exacerbations by 100% through Week 4.
- Connect Biopharma plans to engage with the FDA to align on a Phase 3 program for rademikibart.
- The Phase 2 study enrolled 159 participants globally with an eosinophil count of ≥300 cells/μL.
The big picture
Connect Biopharma's positive Phase 2 data for rademikibart highlights a significant advancement in treating acute exacerbations in COPD patients with type 2 inflammation. The results suggest a potential to reduce healthcare costs and improve patient outcomes, addressing a critical unmet need in chronic disease management. The company's engagement with the FDA will be pivotal in determining the next steps for this promising therapy.
What we're watching
- Regulatory Pathway
- Whether the FDA will align on a Phase 3 program and the timeline for potential approval.
- Market Differentiation
- How rademikibart's unique profile will position it against existing biologics for COPD.
- Commercial Potential
- The pace at which Connect Biopharma can capitalize on the $6 billion healthcare cost opportunity in COPD.
Related topics